Zealand Pharma says Phase 2 ZUPREME-1 trial shows petrelintide cuts weight up to 10.7% at 42 weeks
Bitget2026/09/29 22:03- Zealand Pharma flagged Phase 2 ZUPREME-1 results for petrelintide in obesity, now published, with additional data due at EASD 2026.
- Findings showed clinically meaningful weight loss with gastrointestinal tolerability broadly comparable to placebo, supporting patient persistence potential.
- Study also indicated improvements in cardiometabolic risk markers, strengthening the drug’s profile beyond weight reduction.
- Additional results will be presented on September 30, 2026 at 3:30 p.m. CEST in an EASD oral session.
- A global Phase 3 registrational program for petrelintide monotherapy in chronic weight management has been initiated.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fixed income stalls and stocks take the crown! Wall Street’s big banks report an epic “song of ice and fire” season, marking the darkest hour for a generation of bond traders
As Wall Street's fixed income division came under pressure in the third quarter, its equities division competitors seized this rare opportunity, overshadowing their peers in the fixed income sector.
Rio Tinto on track to release $5 billion in capital after Q3 iron ore sales top estimates
Glencore shares to start trading in Australia as miner hopes to boost valuation
How will the market perform during the remainder of 2026?
Crypto prices
More
